Related Experiment Video
Updated: Jun 13, 2026
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Tumor necrosis factor-alpha in severe corticosteroid-refractory asthma
Jaymin B Morjaria1, K Suresh Babu, Ricardo Polosa
1Southampton General Hospital, Asthma Allergy Inflammation & Repair, Level F, South Academic Block, Mailpoint 810, Southampton SO16 6YD, UK. jbm@soton.ac.uk
Expert Review of Respiratory Medicine
|May 19, 2010
Summary
Tumor necrosis factor-alpha (TNF-alpha) is elevated in severe asthma, contributing to inflammation and airway damage. Targeting TNF-alpha offers a promising treatment for severe, corticosteroid-refractory asthma patients.
Area of Science:
- Immunology
- Pulmonology
- Pharmacology
Background:
- Tumor necrosis factor-alpha (TNF-alpha) is a key proinflammatory cytokine implicated in various inflammatory diseases.
- Elevated TNF-alpha levels and genetic polymorphisms are observed in severe asthma patients.
- Current asthma therapies are insufficient for severe, corticosteroid-refractory cases.
Purpose of the Study:
- To review the evidence for TNF-alpha axis upregulation in severe, corticosteroid-refractory asthma.
- To examine the therapeutic potential of TNF-alpha inhibition in this patient population.
- To discuss the adverse effects associated with TNF-alpha targeted treatments.
Main Methods:
- Literature review of studies investigating TNF-alpha in severe asthma.
- Analysis of clinical trial data on TNF-alpha inhibitors for asthma management.
- Evaluation of safety profiles of TNF-alpha blocking therapies.
Main Results:
- Significant evidence supports TNF-alpha axis upregulation in severe asthma.
- TNF-alpha plays a role in asthma pathogenesis, including inflammation, epithelial damage, and mucus production.
- TNF-alpha inhibitors show potential as an advanced treatment option for difficult-to-treat asthma.
Conclusions:
- Targeting the TNF-alpha pathway represents a significant therapeutic advance for severe, corticosteroid-refractory asthma.
- Further research is warranted to optimize TNF-alpha inhibition strategies and manage potential side effects.
- Understanding TNF-alpha's role is crucial for developing novel asthma treatments.
Related Concept Videos
01:20Asthma: Pathogenesis and Management
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:26Asthma-II: Pathophysiology and Classification
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:13Asthma III: Clinical Manifestations
Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
01:30Asthma-IV: Diagnostic and Management
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms: